Cargando…
PSMA PET in Imaging Prostate Cancer
After prostate malignancy diagnosis, precise determination of disease extent are fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the disease, the longer the survival in many cases. National and international guidelines are based on “classic” imaging technics c...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832487/ https://www.ncbi.nlm.nih.gov/pubmed/35155262 http://dx.doi.org/10.3389/fonc.2022.831429 |
_version_ | 1784648730542080000 |
---|---|
author | Tsechelidis, Ioannis Vrachimis, Alexis |
author_facet | Tsechelidis, Ioannis Vrachimis, Alexis |
author_sort | Tsechelidis, Ioannis |
collection | PubMed |
description | After prostate malignancy diagnosis, precise determination of disease extent are fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the disease, the longer the survival in many cases. National and international guidelines are based on “classic” imaging technics combining radiological and nuclear medicine scans like CT, MRI and bone scintigraphy (BS). The most recent nuclear medicine development is the prostate specific membrane antigen (PSMA) PET and is emerging as the most promising tool of medical imaging, gaining ground every day. Nevertheless, the different onset among multiple studies fails to establish a worldwide admission and incorporation of this technique in guidelines and its position in workaday medical algorithms. It seems that the medical community agrees not to utilize PSMA PET for low-risk patients; intense debate and research is ongoing for its utility in intermediate risk patients. Contrariwise, in high-risk patients PSMA PET is confirmed outperforming CT and BS combined. Additionally, irrespectively to their castration status, patients with biochemical failure should be referred for PSMA PET. Even though PSMA PET reveals more extended disease than expected or exonerates equivalent lesions, thus impacting treatment optimization. Studies being in progress and future trials with clarify whether PSMA PET will be the new gold standard technic for specific groups of patients. |
format | Online Article Text |
id | pubmed-8832487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88324872022-02-12 PSMA PET in Imaging Prostate Cancer Tsechelidis, Ioannis Vrachimis, Alexis Front Oncol Oncology After prostate malignancy diagnosis, precise determination of disease extent are fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the disease, the longer the survival in many cases. National and international guidelines are based on “classic” imaging technics combining radiological and nuclear medicine scans like CT, MRI and bone scintigraphy (BS). The most recent nuclear medicine development is the prostate specific membrane antigen (PSMA) PET and is emerging as the most promising tool of medical imaging, gaining ground every day. Nevertheless, the different onset among multiple studies fails to establish a worldwide admission and incorporation of this technique in guidelines and its position in workaday medical algorithms. It seems that the medical community agrees not to utilize PSMA PET for low-risk patients; intense debate and research is ongoing for its utility in intermediate risk patients. Contrariwise, in high-risk patients PSMA PET is confirmed outperforming CT and BS combined. Additionally, irrespectively to their castration status, patients with biochemical failure should be referred for PSMA PET. Even though PSMA PET reveals more extended disease than expected or exonerates equivalent lesions, thus impacting treatment optimization. Studies being in progress and future trials with clarify whether PSMA PET will be the new gold standard technic for specific groups of patients. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8832487/ /pubmed/35155262 http://dx.doi.org/10.3389/fonc.2022.831429 Text en Copyright © 2022 Tsechelidis and Vrachimis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tsechelidis, Ioannis Vrachimis, Alexis PSMA PET in Imaging Prostate Cancer |
title | PSMA PET in Imaging Prostate Cancer |
title_full | PSMA PET in Imaging Prostate Cancer |
title_fullStr | PSMA PET in Imaging Prostate Cancer |
title_full_unstemmed | PSMA PET in Imaging Prostate Cancer |
title_short | PSMA PET in Imaging Prostate Cancer |
title_sort | psma pet in imaging prostate cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832487/ https://www.ncbi.nlm.nih.gov/pubmed/35155262 http://dx.doi.org/10.3389/fonc.2022.831429 |
work_keys_str_mv | AT tsechelidisioannis psmapetinimagingprostatecancer AT vrachimisalexis psmapetinimagingprostatecancer |